Establishing the putative utility of blood GFAP as a FTD biomarker requires rigorous investigations utilizing large cohorts representing all FTD syndromes, and the comparison of GFAP to more validated biomarkers, such as NfL. Here, GFAP is linked to frontotemporal dementia.